iRhythm Holdings (IRTC) is drawing fresh attention after reporting 23.9% annual revenue growth over the past two years and moving to positive free cash flow, a combination that indicates a maturing business model.
See our latest analysis for iRhythm Holdings.
Despite the move to positive free cash flow and 23.9% annual revenue growth over the past two years, iRhythm Holdings’ share price return is down 40.25% year to date and the 1 year total shareholder return is down 30.65%. However, the 5 year total shareholder return of 59.47% points to a stronger longer term record, with momentum currently under pressure.
If you are interested in other growth stories in digital health and beyond, this could be a good moment to scan 38 healthcare AI stocks
So with iRhythm Holdings shifting to positive free cash flow, yet its stock still down sharply over the past year, is the recent weakness setting up a potential entry point, or is the market already factoring in all that future growth?
Most Popular Narrative: 41.5% Undervalued
According to the most followed narrative, iRhythm Holdings carries a fair value of $178.93 versus a last close of $104.69, putting its current market pricing under scrutiny for investors weighing growth against risk.
The growing push towards population health management, preventative care, and value-based reimbursement is aligning directly with Zio's evidence-supported, scalable monitoring platform, supporting both recurring usage and improved payer coverage, which should drive higher revenues and improved net margins over time.
Curious what sits behind that valuation gap for iRhythm Holdings? The narrative leans on a detailed revenue build, margin lift, and a future earnings multiple that would place the company alongside premium growth stocks. The full story is in how those moving parts are expected to work together over the next few years.
Result: Fair Value of $178.93 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, the iRhythm Holdings story still carries real tension, with regulatory setbacks or sharper competition in cardiac monitoring potentially undermining the growth and valuation narrative that investors are watching.
Find out about the key risks to this iRhythm Holdings narrative.
Another View: What Multiples Say About iRhythm Holdings
While the analyst narrative and fair value of $178.93 frame iRhythm Holdings as undervalued, the current P/S ratio of 4.4x paints a more mixed picture. It sits above the US Medical Equipment industry average of 2.6x, and even above its own fair ratio of 4x, which points to some valuation stretch at today’s price.
Compared with peer averages of 8.3x, that same 4.4x P/S looks more restrained. This suggests the stock is neither obviously cheap nor clearly expensive when set against different reference points. The real question for you is which yardstick you trust more: the broader industry, closer peers, or the fair ratio that the market could move toward over time.
See what the numbers say about this price — find out in our valuation breakdown.
Next Steps
With iRhythm Holdings showing both pressures and promising signals, do you want to rely on one narrative or weigh the trade off yourself? Take a closer look at the 4 key rewards and 1 important warning sign.
Looking for more investment ideas beyond iRhythm Holdings?
If iRhythm Holdings has your attention, do not stop there, use focused stock lists to quickly surface fresh opportunities that match the kind of portfolio you want.
- Target potential upside in smaller companies by reviewing 23 elite penny stocks with strong financials that pair higher risk with stronger financial profiles.
- Zero in on value opportunities by scanning the 44 high quality undervalued stocks that combine quality fundamentals with pricing that may not fully reflect them yet.
- Build staying power into your portfolio by checking the 66 resilient stocks with low risk scores that screen for resilience and lower overall risk scores.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com